Literature DB >> 12666243

Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.

Steve K Teo1, Yong Chen, George W Muller, Roger S Chen, Steve D Thomas, David I Stirling, Reddy S Chandula.   

Abstract

CC-4047 is a racemic second-generation immunomodulatory drug currently in clinical development for various oncologic indications. It has potent effects on key cytokines including tumor necrosis factor-alpha, interleukin (IL-10), and interferon (IFN-gamma). The S-isomer of CC-4047 has been reported to be the more potent enantiomer of the racemate. In this article we report on the rapid racemization of the S-isomer of CC-4047 in human plasma and phosphate-buffered saline. These results support the further development of the racemate instead of the S-isomer. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12666243     DOI： 10.1002/chir.10221

Source DB:  PubMed          Journal:  Chirality        ISSN： 0899-0042            Impact factor:   2.437


  9 in total

1.  Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.

Authors:  Vincent Jacques; Anthony W Czarnik; Thomas M Judge; Lex H T Van der Ploeg; Sheila H DeWitt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

2.  Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

Authors:  Yao Jiang; Jiang Wang; Darlene M Rozewski; Shamalatha Kolli; Chia-Hsien Wu; Ching-Shih Chen; Xiaoxia Yang; Craig C Hofmeister; John C Byrd; Amy J Johnson; Mitch A Phelps
Journal:  J Pharm Biomed Anal       Date:  2013-09-02       Impact factor: 3.935

3.  Population pharmacokinetics of pomalidomide.

Authors:  Yan Li; Yejun Xu; Liangang Liu; Xiaomin Wang; Maria Palmisano; Simon Zhou
Journal:  J Clin Pharmacol       Date:  2015-02-04       Impact factor: 3.126

4.  Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Authors:  Yan Li; Xiaomin Wang; Edward O'Mara; Meletios A Dimopoulos; Pieter Sonneveld; Katja C Weisel; Jeffrey Matous; David S Siegel; Jatin J Shah; Elisabeth Kueenburg; Lars Sternas; Chloe Cavanaugh; Mohamed Zaki; Maria Palmisano; Simon Zhou
Journal:  Clin Pharmacol       Date:  2017-11-08

5.  Structural basis of thalidomide enantiomer binding to cereblon.

Authors:  Tomoyuki Mori; Takumi Ito; Shujie Liu; Hideki Ando; Satoshi Sakamoto; Yuki Yamaguchi; Etsuko Tokunaga; Norio Shibata; Hiroshi Handa; Toshio Hakoshima
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

6.  Distribution of pomalidomide into semen of healthy male subjects after multiple doses.

Authors:  Yan Li; Xiaomin Wang; Liangang Liu; Josephine Reyes; Maria Palmisano; Simon Zhou
Journal:  Clin Pharmacol       Date:  2018-05-07

7.  A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.

Authors:  Yan Li; Liangang Liu; Lian Huang; Xiaomin Wang; Matthew Hoffmann; Josephine Reyes; Maria Palmisano; Simon Zhou
Journal:  Clin Pharmacol       Date:  2018-07-19

8.  In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.

Authors:  Yan Li; Liangang Liu; Xiaomin Wang; Chengyue Zhang; Josephine Reyes; Matthew Hoffmann; Maria Palmisano; Simon Zhou
Journal:  J Clin Pharmacol       Date:  2018-05-15       Impact factor: 3.126

9.  An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.

Authors:  Yan Li; Xiaomin Wang; Liangang Liu; Chengyue Zhang; Diana Gomez; Josephine Reyes; Maria Palmisano; Simon Zhou
Journal:  Clin Pharmacol Drug Dev       Date:  2018-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.